Summary Our previous experimental studies have shown that the best approach to increase the biological anti-tumour activity of interleukin 2 (IL-2) is not co-administration of another cytokine, but the association with immunomodulating neurohormones, in an attempt to reproduce the physiological links between psychoendocrine and immune systems, which play a fundamental role in the regulation of the immune responses. In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone. To confirm these preliminary results, a clinical trial was performed in locally advanced or metastatic patients with solid tumours other than renal cell cancer and melanoma. The study included 80 consecutive patients, who were randomised to be treated with IL-2 alone subcutaneously (3 million IU day-' at 8.00 p.m. 6 days a week for 4 weeks) or IL-2 plus MLT (40 mg day-' orally at 8.00 p.m. every day starting 7 days before IL-2). A complete response was obtained in 3/41 patients treated with IL-2 plus MLT and in none of the patients receiving IL-2 alone. A partial response was achieved in 8/41 patients treated with IL-2 plus MLT and in only 1/39 patients treated with IL-2 alone. Tumour objective regression rate was significantly higher in patients treated with IL-2 and MLT than in those receiving IL-2 alone (11/41 vs 1/39, P<0.001). The survival at 1 year was significantly higher in patients treated with IL-2 and MLT than in the IL-2 group (19/41 vs 6/39, P<0.05). Finally, the mean increase in lymphocyte and eosinophil number was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone; on the contrary, the mean increase in the specific marker of macrophage activation neopterin was significantly higher in patients treated with IL-2 alone. The treatment was well tolerated in both groups of patients. This study shows that the concomitant administration of the pineal hormone MLT may increase the efficacy of low-dose IL-2 subcutaneous therapy.
Several investigators (Grimm et al., 1982) have demonstrated that the anti-tumour immune response is essentially an interleukin 2 (IL-2)-dependent immune phenomenon in human neoplasms, since most cells involved in cancer cell destruction (e.g. NK cells, LAK cells and cytotoxic T lymphocytes) are under physiological stimulatory control exerted by IL-2 itself. Despite the essential role of IL-2 in host anti-tumour immune defences, very few solid tumour histo types, mainly renal cell cancer and melanoma, appear to respond to IL-2 immunotherapy (Dillman et al., 1991) in terms of objective tumour regression. Several cytokines have been evaluated in association with IL-2 in an attempt to improve its clinical results, including interferons, tumour necrosis factor (TNF) and interleukin 6 (IL-6), without, however, any clear amplification of IL-2 efficacy (Atzpodien & Kirchner, 1990) . The lack of efficacy of IL-2 alone in most solid tumour histotypes may depend at least in part on the concomitant generation of suppressive events, mainly mediated by macrophages (Lissoni et al., 1991) . Moreover, immune responses depend not only on immune factors, but also on a great number of interactions between cytokines and neurohormones with immunomodulating effects, in particular the pineal indole melatonin (MLT) (Maestroni et al., 1986) . On the basis of these considerations, we have investigated possible improvements in IL-2 anti-tumour efficacy by a neuroendocrine approach. Our preliminary data have shown that the concomitant administration of the pineal hormone MLT may improve the biological effects (Lissoni et al., 1992) and the anti-tumour activity (Lissoni et al., 1993) of low-dose IL-2 in cancer histotypes that are generally non-responsive to IL-2 alone. MLT could amplify IL-2 activity by antagonising the generation of macrophage-mediated suppressive events (Lissoni et al., 1993) . To confirm these preliminary data, a randomised study was started with low-dose IL-2 vs IL-2 plus MLT in advanced solid neoplasms other than renal cell cancer and malignant melanoma. (Lissoni et al., 1992) . We decided to give IL-2 subcutaneously because of the documented lower toxicity of this route in comparison with the intravenous route of administration Stein et al., 1991) . Moreover, we decided to administer both IL-2 and MLT in the evening because of the higher lympho- 
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The clinical response to therapy in both groups of patients is reported in Table II . Among patients treated with IL-2 plus MLT, CR was achieved in 3/41 (7%). The first CR was seen in a patient with liver metastases from gastric adenocarcinoma, and abdominal node recurrence and who is still alive after a follow-up of 21 months. The second CR was obtained in a patient with locally advanced adenocarcinoma of pancreas who underwent palliative surgery, while the third CR was achieved in a patient with hepatocarcinoma and liver cirrhosis. These patients are still free from disease after 11 and 7 months respectively.
Within the group treated with IL-2 alone, no patient obtained a CR. PR was obtained in 8/41 (19%) patients treated with IL-2 plus MLT (lung cancer, 3; hepatocarcinoma, 2; gastric adenocarcinoma, 1; colon adenocarcinoma, 1; breast cancer, 1), with a median duration of response of 9 + months (range 2-25 +). Therefore, the objective tumour regression rate seen in patients treated with IL-2 plus MLT was 11/41 (26%). Stable disease was observed in 12/41 (30%) patients receiving IL-2 plus MLT, whereas the remaining 18/41 (44%) patients progressed. In the group treated with IL-2 alone, a PR was achieved only in 1/39 (3%) patients, who was affected by locally advanced hepatocarcinoma (duration: 5 months). Eleven other patients (28%) had SD, while the other 27 (69%) progressed. Tumour response rate was significantly higher in patients treated with IL-2 plus MLT than in those receiving IL-2 alone (11/41 vs 1/39, P <0.005). Moreover, the progression-free survival (mean ± s.e.) was significantly higher in patients treated with IL-2 plus MLT than in those treated with IL-2 alone (9 ± 1 vs 4+ 1 months, P <0.05). Finally, according to log-rank test, percentage survival at 1 year was significantly higher in the IL-2 plus MLT group than in patients treated with IL-2 alone (19/41 vs 6/39, P<0.05). The percentage survival at 1 year observed in the two groups of patients is illustrated in Figure 1 .
Toxicity was low in both groups of patients, and in particular no cardiovascular complication occurred. Some sideeffects were apparently less frequent in patients treated with IL-2 plus MLT than in those treated with IL-2 alone, without, however, any significant difference. The main toxicities observed in the two groups of patients are reported in Table  III . As far as the biological data are concerned, no significant difference was seen between patients treated with IL-2 alone or IL-2 plus MLT in the pretreatment values of lymphocytes (1346 ± 186 vs 1274 ± 241 mm-3) and eosinophils (97 ± 13 vs 104 25 mm-3) and serum levels of neopterin (3.9 ± 0.7 vs 3.6 0.5 ng ml-1). The mean increase, as documented by at least six serial measurements in each patient, in the absolute number of lymphocytes and eosinophils was significantly higher in patients receiving IL-2 plus MLT than in those treated with IL-2 alone (lymphocytes, P <0.05; eosinophils, P<0.001). However, the mean increase in serum levels of neopterin observed in the study was significantly higher in patients treated with IL-2 alone than in those treated with IL-2 plus MLT (P<0.05). Mean increases in lymphocyte and eosinophil number and in neopterin levels observed during immunotherapy in both groups of patients are illustrated in Figure 2 .
Discussion
In agreement with the results reported by other authors (Stein et al., 1991) , the present study confirms that low-dose subcutaneous IL-2 is a well-tolerated therapy, capable of causing important immunobiological effects, such as the proliferation of lymphocytes and eosinophils. However, as previously shown by other authors (Stein et al., 1991) (Denicoff et al., 1989) and to affect the activity of the pineal gland (Lissoni et al., 1990) , which represents one of the most important organs involved in the neuroimmunomodulation and in the control of cancer growth (Maestroni et al., 1986) , it could be important to correct the possible alterations in the neuroimmune relationship induced by the exogenous injection of cytokines through an exogenous administration of immunomodulating neurohormones, such as the pineal indole MLT. The present study shows that the concomitant administration of MLT is associated with a greater increase in the number of cells involved in the anti-tumour response during IL-2 immunotherapy, including lymphocytes and eosinophils (West, 1989 with advanced solid tumours treated with low-dose subcutaneous IL-2 immunotherapy. Therefore, neuroendocrinoimmunology, which originated some years ago as a new biological philosophy, may constitute a new therapeutic strategy in cancer, as well as in other human diseases characterised by immune disorders.
